At the end of a two-year follow-up elevated TSH levels normalize or remain unchanged in most the children with subclinical hypothyroidism
© De Luca et al; licensee BioMed Central Ltd. 2010
Received: 15 January 2010
Accepted: 30 January 2010
Published: 30 January 2010
Data about the natural evolution of subclinical hypothyroidism (SH) in pediatric age are very scanty. Moreover all the available reports in both aged and young patients were based on unselected study populations including also patients with either thyroid disorders or other pathological causes that are well known to be able to affect SH development and evolution. Aim of the study by Wasniewska et al was to prospectively evaluate for the first time the natural course of SH in children and adolescents with no underlying diseases and no risk factors that might interfere with the progression of SH. On the basis of the 2-year follow-up results, the Authors concluded that: a) the natural course of TSH values in a pediatric population with idiopathic SH is characterized by a progressive decrease over time; b) the majority of patients (88%) normalized or maintained unchanged their TSH; and c) TSH changes were not associated with changes of either FT4 values or clinical status or auxological parameters.
Study design of this study is very accurate and the results are robust, thus supporting the Authors' conclusions.
Aim of the present Commentary article is to discuss a paper concerning the natural course of idiopathic subclinical hypothyroidism (SH) in childhood and adolescence, that has been very recently published  and was included in the 2009 Pediatric Endocrinology Year Book . Soon after its publication that paper was analyzed and commented by another Author on another journal .
SH is a condition of moderate thyroid failure characterized by normal circulating levels of thyroid hormones with mildly elevated TSH serum concentrations. SH is a common clinical problem in adulthood and elderly, with an average worldwide prevalence that has been reported to be in the range of 4-10% in large general population screening surveys  and 7-26% in studies of elderly . In pediatric age SH prevalence seems to be distinctly lower than in old people, although there are only few epidemiological studies concerning childhood and adolescence [6–8]. According to one of them, SH frequency in adolescents is slightly lower than 2% [8–15].
Data from the literature regarding the natural course of SH are very controversial, probably due to the fact that most the available longterm studies are retrospective. Moreover all the available reports on the spontaneous evolution of SH in both aged and young patients have been based, to now, on unselected study populations including also patients with either thyroid disorders or other pathological causes that are well known to be able to affect SH development and evolution. The risk of progression to overt hypothyroidism, in fact, is known to be greater in those patients with underlying thyroid diseases  and the unfavourable prognostic value of goiter and thyroid autoantibodies was confirmed even in children and adolescents . However, according to one of the few available follow-up studies on juvenile SH, this may be a benign and remitting process with a very low risk of evolution towards frank hypothyroidism .
In their multicenter study Wasniewska et al  have prospectively evaluated for the first time the natural course of SH in children and adolescents with no underlying diseases and no risk factors that might interfere with the progression of SH.
Clinical status, thyroid function, and autoimmunity were prospectively evaluated at entry and after 6, 12, and 24 months in 92 young patients (mean age 8.1 ± 3.0 years) with idiopathic SH.
Diagnosis of SH was based on the finding of at least two consecutive measurements of TSH serum levels between 5 and 10 μIU/ml, in the presence of normal FT4 concentrations. In the entire study population all the etiological causes of SH had been preliminarily excluded at the time of admission.
During the study mean TSH levels showed a trend towards a progressive decrease while FT4 levels remained unchanged. Overall, 38 patients normalized their TSH (group A): 16 patients between 6 and 12 months, and 22 patients between 12 and 24 months. Among the remaining 54 patients, the majority maintained TSH within the baseline values (group B), whereas 11 exhibited a further increase in TSH above 10 μIU/ml (group C). Baseline TSH and FT4 levels were similar in the patients who normalized TSH, compared with those with persistent hyperthyrotropinemia. Even in the patients of group C, both TSH and FT4 at entry were not different with respect to those of group A and B. No patients showed any symptoms of hypothyroidism during follow-up and no changes in both height and body mass index were observed throughout the observation period.
The Authors concluded that: a) the natural course of TSH values in a pediatric population with idiopathic SH is characterized by a progressive decrease over time; b) the majority of patients (88%) normalized or maintained unchanged their TSH; c) TSH changes were not associated with changes of either FT4 values or clinical status or auxological parameters; and d) TSH determination has no reason to be part of the routine check up in children, apart from specific protocols.
SH is a very topical problem, which has been frequently discussed in the last few years by Consensus expert panels in order to define well-established guidelines for medical practice and treatment [12–14]. Moreover, guidelines for SH therapy were frequently discussed in the last years in a high number of editorials, commentaries, controversies or letters to the editor. With regard to SH treatment, the strategy that is shared by the majority of experts is to treat individuals with TSH which is repeatedly higher than 10 μIU/ml. When TSH is lower than 10 μIU/ml and repeatedly between 4.5 (in adults) or 5.5 μIU/ml (in prepubertal children), L-T4 therapy is to be considered only in subjects with positive anti-thyroid antibodies and/or hypothyroid symptoms or signs, whereas the subjects with idiopathic and asymptomatic SH should only be checked and periodically retested  a strategy may be considered as appropriate even at the light of the results of the study by Wasniewska et al, who have clearly demonstrated, through a 2-year follow-up, that in the majority of children with idiopathic SH elevated TSH levels spontaneously normalize or remain unchanged over time . Due to its prospective design and the prolonged follow-up, that study was unique in the context of the studies on juvenile SH, as also underlined by Mazzaferri in his commentary (3). The patients were carefully screened for other causes of SH, including false negative congenital hypothyroidism. None of the patients had any clinical signs or symptoms during the entire follow-up. Moreover, none of the patients showed any symptoms of hypothyroidism during follow-up, and there were no significant changes in both height and body mass index throughout the observation period. The Authors of that study concluded that the natural course of TSH elevations in children and adolescents with idiopathic SH is characterized by a progressive decrease over time and that the majority of patients have a normalization of serum TSH within a 2-year follow-up.
To sum up, we agree with Mazzaferri (3) on the fact that the data in the study by Wasniewska et al (1) are robust, thus supporting the Authors' conclusion that TSH determination has no reason to be part of the routine check-up in children and adolescents, except for specific protocols.
List of abbreviations
- Wasniewska M, Salerno M, Cassio A, Corrias A, Aversa T, Zirilli G, Capalbo D, Bal M, Mussa A, De Luca G: Prostective evaluation of the natural corse of idiopathic subclinical hypothyroidism in childhood and adolescence. Eur J Endocrinol. 2009, 160: 417-421. 10.1530/EJE-08-0625.PubMedView ArticleGoogle Scholar
- Krude H: Thyroid in Yearbook of Pediatric Endocrinology 2009. Karger. Edited by: Carel JC, Hochberg Z. 2009, 37-38.Google Scholar
- Mazzaferri EL: Elevated TSH levels normalize or remain unchanged in the majority of children with subclinical hypothyroidism. Clinical Thyroidology. 2009, 21: 11-13.Google Scholar
- Chu JW, Crapo LM: The treatment of subclinical hypothyroidism is seldom necessary. J Clin Endocrinol Metab. 2001, 86: 4591-4599. 10.1210/jc.86.10.4591.PubMedView ArticleGoogle Scholar
- McDermott MT, Ringway EC: Subclinical hypothyroidism is mild thyroid failure and should be treated. J Clin Endocrinol Metab. 2001, 86: 4585-4590. 10.1210/jc.86.10.4585.PubMedView ArticleGoogle Scholar
- Cetinkaya E, Aslan AT, Vidinlisan S, Ocal G: Height improvement by L-thyroxine treatment in subclinical hypothyroidism. Pediatr Int. 2003, 45: 534-537. 10.1046/j.1442-200X.2003.01786.x.PubMedView ArticleGoogle Scholar
- Paoli-Valari M, Mamàn-Alvarado D, Jimènez-Lòpez V, Arias-Ferreira A, Bianchi G, Arata-Ballabarba G: Frequency of subclinical hypothyroidism among healthy children and those with neurological conditions in the state of Mèrida. 2003, 44: 209-218.Google Scholar
- Wu T, Flowers JW, Tudiver F, Wilson JL, Punyasavatsut N: Subclinical thyroid disorders and cognitive performance among adolescents in the United States. BMC Pediatr. 2006, 6: 12-10.1186/1471-2431-6-12.PubMed CentralPubMedView ArticleGoogle Scholar
- Cooper DS: Clinical practice. Subclinical hypothyroidism. N Engl J Med. 2001, 345: 260-25. 10.1056/NEJM200107263450406.PubMedView ArticleGoogle Scholar
- Radetti G, Gottardi E, Bona G, Corrias A, Salardi S, Loche S, Study Group for Thyroid Diseases of the Italian Society For pediatric Endocrinology and Diabetes (SIEDP/ISPED): The natural history of euthyroid Hashimoto's thyroiditis in children. J Pediatr. 2006, 149: 827-832. 10.1016/j.jpeds.2006.08.045.PubMedView ArticleGoogle Scholar
- Moore DC: Natural course of "subclinical" hypothyroidism in childhood and adolescence. Arch Pediatr Adolesc Med. 1996, 150: 293-297.PubMedView ArticleGoogle Scholar
- Gharib H, Tuttle RM, Baskin HJ, Fish LH, Singer PA, Mc Dermot MT: Subclinicl thyroid dysfunction: a joint statement on management from the American Association of Clinical Endocrinologists, The American Thyroid Association, and The Endocrine Society. J Clin Endocrinol Metab. 2005, 90: 581-585. 10.1210/jc.2004-1231.PubMedView ArticleGoogle Scholar
- Surks MI, Ortiz E, Daniels GH, Sawin CT, Col NF, Cobin RH, Franklyn JA, Hershman JM, Burman KD, Denke MA, Gorman C, Cooper RS, Weissman NJ: Subclinical thyroid disease: scientific review and guidelines for diagnosis and management. JAMA. 2004, 291: 228-238. 10.1001/jama.291.2.228.PubMedView ArticleGoogle Scholar
- American Association of Clinical Endocrinologists: American Association of Clinical Endcorinologists medical guidelines for clinical practice for the evaluation and treatment of hyperthyroidism and hypothyroidism. Endocr Pract. 2002, 8: 457-469.Google Scholar
- Arrigo T, Wasniewska M, Crisafulli G, Lombardo F, Messina MF, Rulli I, Salzano G, Valenzise M, Zirilli G, De Luca F: Subclinical hypothyroidism: The state of the art. J Endocrinol Invest. 2008, 31: 79-84.PubMedView ArticleGoogle Scholar
This article is published under license to BioMed Central Ltd. This is an Open Access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.